Who is on it, and how far along Every drug ChEMBL records acting on TACR1, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved5 Aprepitant Aprepitant SponsorMerck & Co. (MSD) ModalitySmall molecule ActionAntagonist Open trials18 Fosaprepitant Fosaprepitant SponsorQilu Pharmaceutical (Hainan) ModalitySmall molecule ActionAntagonist Open trials16 Netupitant Netupitant SponsorNot known ModalitySmall molecule ActionAntagonist Open trials9 Fosnetupitant Fosnetupitant SponsorHelsinn Healthcare ModalitySmall molecule ActionAntagonist Open trials1 Rolapitant Rolapitant SponsorTersera ModalitySmall molecule ActionAntagonist Open trials1 Phase 34 Elinzanetant Elinzanetant SponsorBayer ModalitySmall molecule ActionAntagonist Open trials4 Tradipitant Tradipitant SponsorVanda Pharmaceuticals ModalitySmall molecule ActionAntagonist Open trials4 Casopitant Casopitant SponsorGSK ModalitySmall molecule ActionAntagonist Open trials0 Serlopitant Serlopitant SponsorVYNE Therapeutics ModalitySmall molecule ActionAntagonist Open trials0 Phase 27 Burapitant Burapitant SponsorSanofi ModalitySmall molecule ActionAntagonist Open trials0 DNK333 DNK333 SponsorNovartis Pharmaceuticals ModalitySmall molecule ActionAntagonist Open trials0 Ezlopitant Ezlopitant SponsorNot known ModalitySmall molecule ActionAntagonist Open trials0 Figopitant Figopitant SponsorNot known ModalitySmall molecule ActionAntagonist Open trials0 Orvepitant Orvepitant SponsorGSK ModalitySmall molecule ActionAntagonist Open trials0 Vestipitant Vestipitant SponsorGSK ModalitySmall molecule ActionAntagonist Open trials0 Vofopitant Vofopitant SponsorGSK ModalitySmall molecule ActionAntagonist Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Neurokinin 1 receptor antagonist. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 28 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy Netupitant Phase 2 Not yet recruiting Fudan University Nov 5, 2026 Prophylaxis for Emetogenic radioTherapy With Akynzeo Netupitant Phase 2 Not yet recruiting University Health Network, Toronto Oct 20, 2026 Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Aprepitant, Fosaprepitant Phase 2 Not yet recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine Sep 30, 2026 Aprepitant for the Treatment of CLIFAHDD Aprepitant, Fosaprepitant Early phase 1 Recruiting The University of Texas Health Science Center at San Antonio Sep 29, 2026 QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration Aprepitant, Fosaprepitant Phase 1 Not yet recruiting Qilu Pharmaceutical (Hainan) Co., Ltd. Sep 14, 2026 Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants Elinzanetant Phase 1 Recruiting Bayer Aug 13, 2026 Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and Vomiting Aprepitant, Fosaprepitant Phase 2 Not yet recruiting Peking University Cancer Hospital & Institute Jul 9, 2026 A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy Aprepitant, Netupitant Early phase 1 Not yet recruiting Ottawa Hospital Research Institute Jun 23, 2026 Aprepitant to Improve Same Day Discharge for TKA Aprepitant Phase 4 Not yet recruiting Endeavor Health Jun 10, 2026 An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms Elinzanetant — Not yet recruiting Bayer Mar 24, 2026 An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC Fosaprepitant Phase 4 Recruiting Shanghai 6th People's Hospital Mar 19, 2026 Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile Aprepitant Phase 2 Recruiting Chinese University of Hong Kong Mar 6, 2026 A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use Tradipitant Phase 3 Recruiting Vanda Pharmaceuticals Mar 3, 2026 A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron Rolapitant Not applicable Not yet recruiting Henan Cancer Hospital Mar 2, 2026 Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen Fosaprepitant Phase 3 Recruiting The Affiliated People's Hospital of Ningbo University Feb 17, 2026 Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery Aprepitant Phase 4 Recruiting Sir Mortimer B. Davis - Jewish General Hospital Jan 28, 2026 A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients Netupitant Phase 4 Not yet recruiting Tianjin Medical University Cancer Institute and Hospital Nov 28, 2025 NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd Netupitant — Enrolling by invitation Yeon Hee Park Aug 20, 2025 Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting Fosaprepitant Phase 3 Not yet recruiting The First Affiliated Hospital of Xinxiang Medical College Aug 15, 2025 Finding Links Between Hot flASHes and CardioVascular Disease Elinzanetant Phase 2 Recruiting Massachusetts General Hospital Jul 22, 2025 Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer Fosaprepitant, Netupitant Phase 3 Recruiting Jiuda Zhao May 1, 2025 Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC) Fosnetupitant Phase 2 Recruiting Helsinn Healthcare SA Apr 1, 2025 Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer Netupitant Phase 4 Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Dec 10, 2024 Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer Netupitant Phase 3 Recruiting Jiuda Zhao Jan 10, 2024 Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness Tradipitant Phase 3 Active, not recruiting Vanda Pharmaceuticals Nov 18, 2023 Tradipitant for Functional Dyspepsia Tradipitant Phase 2 Enrolling by invitation Xiao Jing (Iris) Wang Dec 16, 2022 A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer Elinzanetant Phase 3 Active, not recruiting Bayer Oct 20, 2022 ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection Tradipitant Phase 3 Enrolling by invitation Vanda Pharmaceuticals Mar 30, 2020
Show all 28Diseases most associated with it Open Targets association score, 0 to 1; all associations Cancer 0.60 Cancer Value0.60 Nausea 0.58 Nausea Value0.58 Open Vomiting 0.57 Vomiting Value0.57 Open Chemotherapy-induced nausea and vomiting 0.56 Chemotherapy-induced nausea and vomiting Value0.56 Nausea and vomiting 0.54 Nausea and vomiting Value0.54 Open Post operative nausea and vomiting 0.53 Post operative nausea and vomiting Value0.53 Major depressive disorder 0.53 Major depressive disorder Value0.53 Open Hot flashes 0.45 Hot flashes Value0.45 Open Depressive disorder 0.40 Depressive disorder Value0.40 Open Neoplasm 0.40 Neoplasm Value0.40 Pruritus 0.39 Pruritus Value0.39 Open Atopic eczema 0.38 Atopic eczema Value0.38 Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL249 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. Gene name, function (UniProt P25103 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets